DX0882XK US REVISED CLAIMS – FEBRUARY 2003



WHAT IS CLAIMED IS:

- (amended) A method for impairing movement of a cutaneous lymphocyte-associated antigen⁺ (CLA⁺) memory T-cell within or to the skin of a mammal, said method comprising administering to said mammal an effective amount of an antibody against cutaneous-T-cell-attracting chemokine (CTACK), whereby administration of said antibody impairs movement of said cutaneous lymphocyte-associated antigen⁺ memory T-cell within or to the skin of said mammal.
- 3. (amended) The method of Claim 1, wherein said movement is within said skin.
- 4. (amended) The method of Claim 1, wherein said antibody neutralizes cutaneous-T-cell-attracting chemokine.
- 22. (amended) A method of <u>for</u> treating a patient suffering from a skin disorder comprising administering an effective amount of an <u>antagonist antibody</u> against <u>CTACK cutaneous-T-cell-attracting chemokine</u>.
- 23. The method of Claim 22, wherein the antagonist is an antibody.
- 24. (new) The method of Claim 1, wherein said administering is local, systemic, topical, subcutaneous, intradermal, or transdermal.
- 25. (new) The method of Claim 1, wherein said cutaneous lymphocyte-associated antigen memory T-cell moves into the dermis or epidermis of said skin.
- 26. (new) The method of Claim 22, wherein said skin disorder is inflammation.
- 27. (new) The method of Claim 22, wherein said skin disorder is allergic-contact dermatitis.
- 28. (new) The method of Claim 22, wherein said skin disorder is psoriasis.
- 29. (new) The method of Claim 22, wherein said skin disorder is wound healing,
- 30. (new) The method of Claim 22, wherein said skin disorder is cancer.
- 31. (new) The method of Claim 22, wherein said skin disorder is carcinoma.
- 32. (new) The method of Claim 22, wherein said skin disorder is infection.
- 33. (new) The method of Claim 32, wherein said infection is microbial, viral, or parasitic.